Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025

    Al Qaeda Refuses to Die – The Cipher Brief

    4. Juni 2025

    The Pros and Cons of Bluetooth Speakers

    4. Juni 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»Health»Proton’s device aims to help those with kidney disease and cut heart-failure risks
    Health

    Proton’s device aims to help those with kidney disease and cut heart-failure risks

    HealthradarBy Healthradar1. Juni 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Proton’s device aims to help those with kidney disease and cut heart-failure risks
    Share
    Facebook Twitter LinkedIn Pinterest Email


    People with chronic kidney disease or those at risk of heart failure are greatly affected by potassium imbalances in the body. These can even be life-threatening. While wearable glucose monitors are now commonplace and have transformed the lives of diabetes patients, potassium monitoring is in its infancy, as it’s hard to do. Now startups are emerging to address the problem. 

    Proton Intelligence is a Canada-based startup developing a continuous potassium monitoring product. It has now closed a $6.95 million seed round led by SOSV. Clinical trials are underway for the product, which is due to launch in 2025.

    Proton is developing a small device that would be inserted just below the skin in order to monitor potassium levels. This would connect with a smartphone app so that patients can monitor their potassium levels and get notifications if their levels move out of a safe range, based on lifestyle choices like diet or medication.

    A clinician dashboard will provide a view of a patient’s potassium trends, and care teams will be able to use the data to fine-tune therapies.

    The company was co-founded by CEO Sahan Ranamukhaarachchi (based in Vancouver, Canada) and CSO Victor Cadarso (based in Melbourne).

    The two founded the startup after working on wearable biosensors as researchers in Switzerland 10 years ago. Ranamukhaarachchi went on to found a skin-based drug delivery startup (Microdermics), while Cadarso  became a professor in micro- and nano-sensors at Monash University in Melbourne. Proton has a commercial-focused HQ in Canada and a wholly owned R&D-focused subsidiary in Melbourne, Australia.

    Ranamukhaarachchi told TechCrunch the team did over 100 in-depth interviews with care teams to research their product. “These highlighted the devastating consequences of ‘flying blind’ when managing potassium levels, because delays in monitoring often lead to preventable hospitalizations, stopping therapies, or even sudden cardiac death,” he said.

    He described how patients talked about “a constant fear of potassium imbalances, questioning if eating a single banana or missing a blood test” could affect their health or even put their lives at risk. 

    The problem is real. Some 10% of the population worldwide is affected by chronic kidney disease, and thousands die each year because they do not have access to affordable treatment. 

    Proton competes with a number of other emerging firms in the sector. 

    AliveCor estimates potassium levels indirectly by detecting cardiac activity (it’s raised $154.3 million to date). Alio does potassium monitoring in dialysis patients (it has raised $46 million). Renalyse out of Spain measures potassium via finger-prick blood samples (it has raised €1 million). There are, of course, several others.

    That said, Proton’s founders claim that its solution will be more scalable: “No other technology currently offers this level of usability, accuracy, and clinical impact,” said Ranamukhaarachchi.

    In a statement, Mohan S. Iyer, general partner at SOSV, said: “We are proud to be the first institutional investor in Proton Intelligence … and we are excited to continue to support them as they move into clinical validation.”

    The seed round also saw participation from We Venture Capital, Tenmile, LongeVC, 15th Rock, Exor, and Trampoline Venture Partners. 



    Source link

    aims cut Device disease Health HealthTech heartfailure kidney medtech Protons risks wearable devices wearables
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticlePEPFAR funding cuts will lead to up to 74,000 excess HIV deaths in Africa by 2030, experts warn
    Next Article The FDA is making it more difficult for Americans to get vaccinated for covid 
    ekass777x
    Healthradar
    • Website

    Related Posts

    Health

    Inside the Bloodbath at the NIH. Sources say that a climate of fear has spread throughout the agency as the Trump administration takes a hatchet to its core functions.

    5. Juni 2025
    Health

    3-Year Exercise Program Improves Colon Cancer Survival Rates

    4. Juni 2025
    Health

    watchOS 12: 3 things I expect to see Tim Cook announce at this year’s WWDC

    3. Juni 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Which Online Poker Game Should You Play?

    31. Mai 20259 Views

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views

    One In Four European Firms Ban Grok AI Chatbot Over Security Concerns

    1. Juni 20252 Views

    Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

    1. Juni 20252 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Which Online Poker Game Should You Play?

    31. Mai 20259 Views

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20254 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.